Market OpportunityThe data validates the efficacy and market opportunity for Haduvio, with the IPF Chronic Cough data exceeding expectations and showing market potential could be larger than anticipated.
Stock ValuationThe stock is considered undervalued, with the IPF-CC opportunity alone being seen as a $1 billion plus opportunity for TRVI.
Strategic FocusTRVI's strategic focus on IPF-CC comes front-and-center as the key value driver, with potential for specialty pricing and concentrated operational investments for commercialization.